Your browser doesn't support javascript.
loading
An unexpected dynamic binding mode between coagulation factor X and Rivaroxaban reveals importance of flexibility in drug binding.
Qu, Si-Ying; Xu, Qin; Wu, Wenman; Li, Fang; Li, Cheng-Dong; Huang, Ran; Ding, Qiulan; Wei, Dong-Qing.
Affiliation
  • Qu SY; State Key Laboratory of Microbial Metabolism and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
  • Xu Q; State Key Laboratory of Microbial Metabolism and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
  • Wu W; Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Li F; State Key Laboratory of Microbial Metabolism and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
  • Li CD; State Key Laboratory of Microbial Metabolism and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
  • Huang R; State Key Laboratory of Microbial Metabolism and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
  • Ding Q; Department of Materials Technology and Engineering, Research Institute of Zhejiang University-Taizhou, Taizhou, Zhejiang, China.
  • Wei DQ; Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Chem Biol Drug Des ; 94(3): 1664-1671, 2019 09.
Article de En | MEDLINE | ID: mdl-31108011
ABSTRACT
Rivaroxaban (RIV) is a direct oral anticoagulant (DOAC) targeting activated coagulation factor X (FXa). An earlier study reported the F174A mutant of FXa resistant to a RIV-like inhibitor, Apixaban. In current study, the detailed molecular mechanism of the resistance has been explored by molecular dynamics simulations on the impaired interactions between RIV and FXa in the damaged S4 pocket of F174A mutant. Besides, an unexpected relative stable binding mode of S1'S1 was revealed, which required dynamic motions of Gln192 and Gln61 to allow the morpholinone moiety of RIV to shift into the S1' pocket and form strong interactions. These dynamic motions of RIV and critical residues might be important in drug design for direct inhibitors of coagulation factors.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Pyrazoles / Pyridones / Facteur X / Protéines mutantes / Simulation de dynamique moléculaire / Inhibiteurs du facteur Xa / Rivaroxaban / Anticoagulants Type d'étude: Prognostic_studies Limites: Humans Langue: En Journal: Chem Biol Drug Des Sujet du journal: BIOQUIMICA / FARMACIA / FARMACOLOGIA Année: 2019 Type de document: Article Pays d'affiliation: Chine

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Pyrazoles / Pyridones / Facteur X / Protéines mutantes / Simulation de dynamique moléculaire / Inhibiteurs du facteur Xa / Rivaroxaban / Anticoagulants Type d'étude: Prognostic_studies Limites: Humans Langue: En Journal: Chem Biol Drug Des Sujet du journal: BIOQUIMICA / FARMACIA / FARMACOLOGIA Année: 2019 Type de document: Article Pays d'affiliation: Chine